HealthMore in Health→
Otsuka’s $700 Million Upfront Deal for Transcend Signals Continued Bet on Next-Generation Neuropsychiatric Drugs
Key Takeaways
- Otsuka will pay $700 million upfront to acquire Transcend Therapeutics.
- The transaction is worth roughly $1.2 billion in total.
- The deal strengthens pharma interest in neuropsychiatric drugs linked to psychedelic therapeutic promise.
DE
DT Editorial Team··via endpoints.news